GLPwatch
Papers (9189)
Page 44 of 154, ranked by citation count.
- Cardiovascular safety and benefits of GLP-1 receptor agonists.
- Adjuvant Liraglutide and Insulin Versus Insulin Monotherapy in the Closed-Loop System in Type 1 Diabetes: A Randomized Open-Labeled Crossover Design Trial.
- Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes.
- Delayed Administration of the Glucagon-Like Peptide 1 Analog Liraglutide Promoting Angiogenesis after Focal Cerebral Ischemia in Mice.
- The preventive effect of liraglutide on the lipotoxic liver injury via increasing autophagy.
- Cost-Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity.
- Modulation of myocardial injury and collagen deposition following ischaemia-reperfusion by linagliptin and liraglutide, and both together.
- Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: sub study of the phase II/III ExSTRESS randomized trial.
- Exendin-4 increases oxygen consumption and thermogenic gene expression in muscle cells.
- Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs).
- Tirzepatide Once Weekly for the Treatment of Obesity.
- The GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release.
- Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways.
- Exenatide Facilitates Recovery from Oxaliplatin-Induced Peripheral Neuropathy in Rats.
- Cardiac and Renovascular Complications in Type 2 Diabetes--Is There Hope?
- Obesity medication lorcaserin activates brainstem GLP-1 neurons to reduce food intake and augments GLP-1 receptor agonist induced appetite suppression.
- Liraglutide suppresses atrial electrophysiological changes.
- Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials.
- Liraglutide Enhances Autophagy and Promotes Pancreatic β Cell Proliferation to Ameliorate Type 2 Diabetes in High-Fat-Fed and Streptozotocin-Treated Mice.
- Exenatide-induced eosinophilic sclerosing lipogranuloma at the injection site.
- Exenatide improves random-pattern skin flap survival via TFE3 mediated autophagy augment.
- Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective.
- The bone-preserving effects of exendin-4 in ovariectomized rats.
- Liraglutide enhances the effect of checkpoint blockade in lung and liver cancers through the inhibition of neutrophil extracellular traps.
- The effects of liraglutide in mice with diet-induced obesity studied by metabolomics.
- The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes.
- Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice.
- Liraglutide ameliorates palmitate-induced insulin resistance through inhibiting the IRS-1 serine phosphorylation in mouse skeletal muscle cells.
- Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes.
- Hydrogel Drug Delivery System Using Self-Cleaving Covalent Linkers for Once-a-Week Administration of Exenatide.
- Postprandial serum C-peptide is a useful parameter in the prediction of successful switching to liraglutide monotherapy from complex insulin therapy in Japanese patients with type 2 diabetes.
- Pre-clinical evaluation of [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 for imaging of insulinoma.
- Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
- A vitamin B12 conjugate of exendin-4 improves glucose tolerance without associated nausea or hypophagia in rodents.
- Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom.
- Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment.
- Evidence That in Uncontrolled Diabetes, Hyperglucagonemia Is Required for Ketosis but Not for Increased Hepatic Glucose Production or Hyperglycemia.
- Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.
- Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions.
- Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect.
- Protection of exenatide for retinal ganglion cells with different glucose concentrations.
- Exendin-4 upregulates the expression of Wnt-4, a novel regulator of pancreatic β-cell proliferation.
- Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study.
- New developments in diabetes management: medications of the 21st century.
- Pancreatitis: a potential complication of liraglutide?
- Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association.
- Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review.
- Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.
- Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study.
- Application of DBS for quantitative assessment of the peptide Exendin-4; comparison of plasma and DBS method by UHPLC-MS/MS.
- Neurotrophic and neuroprotective properties of exendin-4 in adult rat dorsal root ganglion neurons: involvement of insulin and RhoA.
- Liraglutide Promotes the Osteogenic Differentiation in MC3T3-E1 Cells via Regulating the Expression of Smad2/3 Through PI3K/Akt and Wnt/β-Catenin Pathways.
- Development of 68Ga- and 89Zr-Labeled Exendin-4 as Potential Radiotracers for the Imaging of Insulinomas by PET.
- Exendin-4, an analogue of glucagon-like peptide-1, attenuates hyperalgesia through serotonergic pathways in rats with neonatal colonic sensitivity.
- Protective effect of Liraglutide on diabetic retinal neurodegeneration via inhibiting oxidative stress and endoplasmic reticulum stress.
- Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks.
- Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes.
- Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.